What the FDA labels say about taking them together
Deferasirox and theophylline
Deferasirox's FDA label of January 28, 2026 names theophylline in its drug interactions section; the theophylline label PlainMeds reads does not name deferasirox. The deferasirox label: “Consider repaglinide dose reduction and monitor blood glucose levels. Avoid the use of JADENU with theophylline as theophylline levels could be increased.”
Check it at the source: the deferasirox FDA label on DailyMed (effective January 28, 2026, Novartis Pharmaceuticals Corporation); the theophylline FDA label on DailyMed (effective March 10, 2026, Strides Pharma Science Limited).
What does the deferasirox label say about theophylline?
Deferasirox label, drug interactionsConsider repaglinide dose reduction and monitor blood glucose levels. ( 7.3 ) Avoid the use of Exjade with CYP1A2 substrate theophylline. ( 7.4 ) Deferasirox increases exposure of busulfan.
Jadenu label (Novartis Pharmaceuticals Corporation, January 26, 2018), drug interactionsConsider repaglinide dose reduction and monitor blood glucose levels. ( 7.3 ) Avoid the use of JADENU with theophylline as theophylline levels could be increased.
Source: FDA drug label (Jadenu, NDA206910), Novartis Pharmaceuticals Corporation, effective December 11, 2025 (SPL set fee89140-fff1-4443-9f42-24ac004fcda1), via openFDA
Source: FDA drug label (Jadenu, NDA207968), Novartis Pharmaceuticals Corporation, effective January 26, 2018 (SPL set 87f79cd1-2799-478f-a591-85d20c44f207), via openFDA
Source: FDA drug label (Exjade), Novartis Pharmaceuticals Corporation, effective January 28, 2026 (SPL set 3495a70c-870c-4968-940e-8baea152cf85), via openFDA; the full label on DailyMed
What does the theophylline label say about deferasirox?
Theophylline's label (effective March 10, 2026) does not name deferasirox in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Theophylline), Strides Pharma Science Limited, effective March 10, 2026 (SPL set b7a90ccf-9c32-40cc-9008-7e55b3da4dfd), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Deferasirox | Theophylline | |
|---|---|---|
| Labeled for | n/a | Asthma |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $1.25 per tablet 360 mg tablet | $0.330 per tablet 300 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once